Should I buy or sell Apollomics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollomics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" APLM shares. View APLM analyst ratings or view top-rated stocks .

What is Apollomics' stock price target for 2024?

1 Wall Street research analysts have issued 12-month target prices for Apollomics' stock. Their APLM share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 961.3% from the stock's current price. View analysts price targets for APLM or view top-rated stocks among Wall Street analysts .

How have APLM shares performed in 2024?

Apollomics' stock was trading at $0.9650 on January 1st, 2024. Since then, APLM shares have decreased by 51.2% and is now trading at $0.4711. View the best growth stocks for 2024 here .

Are investors shorting Apollomics?

Apollomics saw a increase in short interest in March. As of March 31st, there was short interest totaling 155,100 shares, an increase of 238.6% from the March 15th total of 45,800 shares. Based on an average trading volume of 216,000 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.2% of the company's shares are short sold. View Apollomics' Short Interest .

When is Apollomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, June 27th 2024. View our APLM earnings forecast .

What ETFs hold Apollomics' stock?

ETFs with the largest weight of Apollomics (NASDAQ:APLM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) . Loncar China Biopharma ETF (CHNA) .

Who are Apollomics' major shareholders?

Apollomics' stock is owned by a number of retail and institutional investors. Top institutional investors include Powell Investment Advisors LLC (0.15%).

How do I buy shares of Apollomics?

Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:APLM

Apollomics (APLM) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free APLM Stock Alerts

$0.47

-0.04 (-7.45%)

(As of 03:59 PM ET)

Compare

Today's Range: $0.46
▼
$0.51
50-Day Range: $0.51
▼
$0.77
52-Week Range: $0.46
▼
$6.50

Volume: 167,623 shs
Average Volume: 220,306 shs
Market Capitalization: $42.24 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Get Apollomics alerts:

Apollomics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 961.3% Upside
$5.00 Price Target
Short Interest: Healthy
0.24% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.94 out of 5 stars

Medical Sector

848th out of 918 stocks

Pharmaceutical Preparations Industry

387th out of 419 stocks

3.5

Analyst's Opinion

Consensus Rating
Apollomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Apollomics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.24% of the float of Apollomics has been sold short.
Short Interest Ratio / Days to Cover
Apollomics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Apollomics has recently increased by 238.65%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Apollomics does not currently pay a dividend.
Dividend Growth
Apollomics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APLM.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Apollomics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for APLM on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Apollomics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Apollomics insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 19.13% of the stock of Apollomics is held by institutions.

0.6

Earnings and Valuation

Price to Book Value per Share Ratio
Apollomics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Apollomics Stock (NASDAQ:APLM)

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

APLM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APLM Stock News Headlines

April 17, 2024 | msn.com

Apollomics (APLM) Price Target Decreased by 58.93% to 5.87

April 16, 2024 | finance.yahoo.com

Apollomics, Inc. (APLM) Interactive Stock Chart - Yahoo Finance

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 10, 2024 | globenewswire.com

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

April 2, 2024 | finance.yahoo.com

Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

March 28, 2024 | msn.com

Apollomics GAAP EPS of -$2.32

March 28, 2024 | globenewswire.com

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

March 4, 2024 | finance.yahoo.com

Apollomics Names Matthew Plunkett as Chief Financial Officer

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 4, 2024 | globenewswire.com

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

February 22, 2024 | benzinga.com

Apollomics Stock (NASDAQ:APLM), Short Interest Report

January 20, 2024 | finanznachrichten.de

Apollomics Inc.: Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

January 19, 2024 | finance.yahoo.com

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

January 17, 2024 | stockhouse.com

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

January 3, 2024 | finance.yahoo.com

Apollomics Completes Patient Enrollment for Phase 3 Trial of Leukemia Treatment

December 17, 2023 | morningstar.com

Apollomics Inc Ordinary Shares - Class A APLM

December 12, 2023 | morningstar.com

Apollomics Inc Ordinary Shares - Class A

December 7, 2023 | finance.yahoo.com

Apollomics Presents Data from Phase 2 Clinical Trials of Lung Cancer Medication

December 4, 2023 | finance.yahoo.com

Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

November 28, 2023 | ca.finance.yahoo.com

Apollomics, Inc. (APLM)

November 28, 2023 | finance.yahoo.com

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

November 16, 2023 | marketwatch.com

Apollomics Shares More Than Double on Partner's Approval for Commercialization of Vebreltinib

November 16, 2023 | msn.com

Why Is Cancer Firm Apollomics Stock Trading Higher Today?

November 16, 2023 | finance.yahoo.com

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

October 31, 2023 | finance.yahoo.com

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

October 27, 2023 | msn.com

Apollomics stock soars 76% following positive report for brain cancer therapy

October 27, 2023 | benzinga.com

What's Going On With Apollomics Inc Stock?

See More Headlines

Receive APLM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Next Earnings (Estimated): 6/27/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:APLM
CUSIP: N/A
CIK: 1944885
Web: www.apollomicsinc.com
Phone: 886-2-7713-7952
Fax: N/A
Employees: 45
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +963.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.95
Quick Ratio: 2.95

Sales & Book Value

Annual Sales: $1.22 million
Price / Sales: 34.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.48 per share
Price / Book: 0.98

Miscellaneous

Outstanding Shares: 89,500,000
Free Float: N/A
Market Cap: $42.07 million
Optionable: Not Optionable
Beta: 1.30

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Guo-Liang Yu Ph.D. (Age 61)
Co-Founder, CEO & Executive Chairman
Dr. Sanjeev Redkar MBA (Age 55)
Ph.D., Co-Founder, President & Executive Director
Dr. Matthew James Plunkett Ph.D. (Age 52)
Chief Financial Officer
Dr. Kin-Hung Yu M.D. (Age 62)
Chief Medical Officer
Dr. Chinglin Lai Ph.D.
Senior Vice President of Biostatistics & Data Management

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

APLM Stock Analysis - Frequently Asked Questions

Should I buy or sell Apollomics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollomics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" APLM shares.
View APLM analyst ratings or view top-rated stocks.
What is Apollomics' stock price target for 2024?: 1 Wall Street research analysts have issued 12-month target prices for Apollomics' stock. Their APLM share price targets range from $5.00 to $5.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 961.3% from the stock's current price.
View analysts price targets for APLM or view top-rated stocks among Wall Street analysts.
How have APLM shares performed in 2024?: Apollomics' stock was trading at $0.9650 on January 1st, 2024. Since then, APLM shares have decreased by 51.2% and is now trading at $0.4711.
View the best growth stocks for 2024 here.
Are investors shorting Apollomics?: Apollomics saw a increase in short interest in March. As of March 31st, there was short interest totaling 155,100 shares, an increase of 238.6% from the March 15th total of 45,800 shares. Based on an average trading volume of 216,000 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.2% of the company's shares are short sold.
View Apollomics' Short Interest.

When is Apollomics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, June 27th 2024.
View our APLM earnings forecast.
What ETFs hold Apollomics' stock?: ETFs with the largest weight of Apollomics (NASDAQ:APLM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).
Who are Apollomics' major shareholders?: Apollomics' stock is owned by a number of retail and institutional investors. Top institutional investors include Powell Investment Advisors LLC (0.15%).
How do I buy shares of Apollomics?: Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APLM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Apollomics (APLM) Stock Price, News & Analysis

Apollomics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Institutions

Earnings and Valuation

Price to Book Value per Share Ratio

About Apollomics Stock (NASDAQ:APLM)

APLM Stock Price History

APLM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

APLM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™